HK1253098A1 - 用於治疗癌症的mdm2抑制剂的给药方案 - Google Patents

用於治疗癌症的mdm2抑制剂的给药方案 Download PDF

Info

Publication number
HK1253098A1
HK1253098A1 HK18112485.7A HK18112485A HK1253098A1 HK 1253098 A1 HK1253098 A1 HK 1253098A1 HK 18112485 A HK18112485 A HK 18112485A HK 1253098 A1 HK1253098 A1 HK 1253098A1
Authority
HK
Hong Kong
Prior art keywords
mdm2 inhibitor
dosage regimen
treating
treating cancers
subject
Prior art date
Application number
HK18112485.7A
Other languages
English (en)
Chinese (zh)
Inventor
Ngai-chiu Archie TSE
Shengli CAI
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of HK1253098A1 publication Critical patent/HK1253098A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18112485.7A 2015-10-23 2016-10-21 用於治疗癌症的mdm2抑制剂的给药方案 HK1253098A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245632P 2015-10-23 2015-10-23
US62/245,632 2015-10-23

Publications (1)

Publication Number Publication Date
HK1253098A1 true HK1253098A1 (zh) 2019-06-06

Family

ID=57349101

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112485.7A HK1253098A1 (zh) 2015-10-23 2016-10-21 用於治疗癌症的mdm2抑制剂的给药方案

Country Status (8)

Country Link
US (3) US20180296547A1 (enExample)
EP (1) EP3364972A1 (enExample)
JP (4) JP6855472B2 (enExample)
KR (1) KR20180064540A (enExample)
CN (2) CN113521069A (enExample)
HK (1) HK1253098A1 (enExample)
TW (3) TW202332444A (enExample)
WO (1) WO2017069289A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
HK1251165A1 (en) 2015-04-13 2019-01-25 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案
US10409015B1 (en) 2015-12-15 2019-09-10 Optomind Inc. Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP4384166A1 (en) * 2021-08-09 2024-06-19 Boehringer Ingelheim International GmbH Oral composition comprising a mdm2-antagonist for cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007228784B2 (en) * 2006-03-22 2012-03-08 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53
JP2010501558A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）との組み合わせ
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
DK2684880T3 (en) * 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
US9937178B2 (en) * 2011-12-07 2018-04-10 Duke University Methods of identifying and using MDM2 inhibitors
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP5958208B2 (ja) * 2012-09-10 2016-07-27 凸版印刷株式会社 包装袋
US10030028B2 (en) * 2013-09-04 2018-07-24 Daiichi Sankyo Company, Limited Method for producing a spirooxindole derivative
US20160333419A1 (en) * 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
KR102595395B1 (ko) * 2015-02-20 2023-10-27 다이이찌 산쿄 가부시키가이샤 암의 병용 치료법
HK1251165A1 (en) * 2015-04-13 2019-01-25 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
HK1253098A1 (zh) * 2015-10-23 2019-06-06 Daiichi Sankyo Company, Limited 用於治疗癌症的mdm2抑制剂的给药方案

Also Published As

Publication number Publication date
US20220071975A1 (en) 2022-03-10
JP6855472B2 (ja) 2021-04-07
JP2021098750A (ja) 2021-07-01
CN108135892A (zh) 2018-06-08
US20180296547A1 (en) 2018-10-18
JP2024164122A (ja) 2024-11-26
CN113521069A (zh) 2021-10-22
TW202515561A (zh) 2025-04-16
EP3364972A1 (en) 2018-08-29
WO2017069289A1 (en) 2017-04-27
TW201722427A (zh) 2017-07-01
JP7192011B2 (ja) 2022-12-19
JP2023025214A (ja) 2023-02-21
JP2018531273A (ja) 2018-10-25
TWI806822B (zh) 2023-07-01
US11058673B2 (en) 2021-07-13
KR20180064540A (ko) 2018-06-14
TW202332444A (zh) 2023-08-16
US20190201386A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
HK1253098A1 (zh) 用於治疗癌症的mdm2抑制剂的给药方案
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MY187540A (en) Compounds active towards bromodomains
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
IN2013MU03583A (enExample)
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
IN2014MU00303A (enExample)
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
BR112017024163A2 (pt) compostos bicíclicos
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
EP3181136A4 (en) Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
IL271013B (en) Allosteric egfr inhibitors with a modified isoindole, pharmaceutical preparations containing them and their use in medical treatment and/or preventive treatment of cancer
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3290051A4 (en) Pharmaceutical composition for treating and/or preventing cancer
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.